T-Cypher Bio is an Oxford-based biotechnology company developing next-generation immune-engaging medicines for cancer and autoimmune disease. Founded in 2020, T-Cypher emerged from Orbit Discovery to focus on developing a functional, high-throughput platform to select therapeutically relevant targets and identify potent, target-specific T cell receptors (TCRs) for the treatment of solid tumours and other indications.
The company’s approach centres on human leukocyte antigen (HLA) proteins, which continuously transport cellular signature peptides to the cell surface, allowing the immune system to monitor the health of individual cells. T-Cypher investigates disease biology at this level, identifying molecular signatures to discover novel, disease-specific targets. These insights are used to identify disease-relevant targets and develop new medicines. The company has a pipeline of immune engagers against novel targets across a range of solid tumours and selected autoimmune diseases.
Professor Graham Ogg
Co-founder and Chair of the Scientific Advisory Board
Leadership Profile
Professor Graham Ogg is co-founder of T-Cypher Bio and a world authority in T cell immunology. He is Professor of Dermatology at the University of Oxford and Deputy Director of the MRC Translational Immune Discovery Unit. His research focuses on understanding the role of human cutaneous immune responses in disease, treatment and vaccination, with particular emphasis on T cells and their role in inflammatory skin disease. He has been recognised as an NIHR Senior Investigator and a Fellow of the Academy of Medical Sciences. His expertise in TCR and antigen discovery provided the scientific foundation on which T-Cypher was built.
